Novartis Upbeat As Ofatumumab Data Delivers In MS
Novartis looks to differentiate ofatumumab from Roche's entrenched MS blockbuster Ocrevus, stressing that patients can inject the therapy at home.
Novartis looks to differentiate ofatumumab from Roche's entrenched MS blockbuster Ocrevus, stressing that patients can inject the therapy at home.